Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 186-192

  Myc, Andrzej ^a   Kukowska Latallo, Jolanta ^a   Cao, Peter ^a   Swanson, Ben ^a   Battista, Julianna ^a   Dunham, Thomas ^a   Baker, James R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Coculture assay; Dendrimer; Heterogeneous xenograft tumor model; Methotrexate; Neoplasm; Targeted drug delivery

Indexed keywords

DENDRIMER; FOLATE RECEPTOR; FOLIC ACID; METHOTREXATE; POLYAMIDOAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL HETEROGENEITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLIC ACID; HUMANS; KB CELLS; METHOTREXATE; MICE; MICE, INBRED NOD; MICE, SCID; NANOSTRUCTURES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76149111605     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328334560f     Document Type: Article

References (48)

1. Malhotra V, Perry MC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther 2003; 2 (4 Suppl 1):S2-S4.
2. Read TA, Thorsen F, Bjerkvig R. Localised delivery of therapeutic agents to CNS malignancies: old and new approaches. Curr Pharm Biotechnol 2002; 3:257-273.
3. Albrecht H, DeNardo SJ. Recombinant antibodies: from the laboratory to the clinic. Cancer Biother Radiopharm 2006; 21:285-304.
4. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11:812-818.
5. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005; 10:35-43.
6. Pinto RC, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2:53-65.
7. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006; 384:620-630.
8. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY,Williams ED, Porter CJ. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol Pharm 2009; 6:1190-1204.
9. Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol 2002; 6:742-748.
10. Frey H, Haag R. Dendritic polyglycerol: a new versatile biocompatiblematerial. J Biotechnol 2002; 90:257-267.
11. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release 1999; 60:149-160.
12. Kannan S, Kolhe P, Raykova V, Glibatec M, Kannan RM, Lieh-Lai M, Bassett D. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed 2004; 15:311-330.
13. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. Synthesis, cellular transport, and activity of polyamidoamine dendrimermethylprednisolone conjugates. Bioconjug Chem 2005; 16:330-337.
14. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan R. Hyperbranched polymer-drug conjugates with high drug payload for enhanced cellular delivery. Pharm Res 2004; 21:2185-2195.
15. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 2003; 259:143-160.
16. Kono K, Liu M, Frechet JM. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug Chem 1999; 10:1115-1121.
17. Ooya T, Lee J, Park K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003; 93:121-127.
18. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, Baker JR Jr. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 2005; 48:3729-3735.
19. Wiwattanapatapee R, Carreno-Gomez B, Malik N, Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm Res 2000; 17:991-998.
20. Cheng Y, Wang J, Rao T, He X, Xu T. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci 2008; 13:1447-1471.
21. Gupta U, Agashe HB, Asthana A, Jain NK. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 2006; 7:649-658.
22. Li Y, Cheng Y, Xu T. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr Drug Discov Technol 2007; 4:246-254.
23. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009; 71:445-462.
24. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomed 2008; 3:679-702.
25. Svenson S, Tomalia DA. Dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev 2005; 57:2106-2129.
26. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 2006; 17:275-283.
27. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65:5317-5324.
28. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 2005; 48:5892-5899.
29. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002; 6:466-471.
30. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002; 19:1310-1316.
31. Myc A, Douce TB, Ahuja N, Kotlyar A, Kukowska-Latallo J, Thomas TP, Baker JR Jr. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs 2008; 19:143-149.
32. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15:1174-1181.
33. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006; 17:1109-1115.
34. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR Jr. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun 2005; 46:5739-5741.
35. Bosanquet AG, Burlton AR, Bell PB, Harris AL. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Br J Cancer 1997; 76:511-518.
36. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275:343-349.
37. Leith JT, Michelson S, Faulkner LE, Bliven SF. Growth properties of artificial heterogeneous human colon tumors. Cancer Res 1987; 47:1045-1051.
38. Leith JT, Faulkner LE, Bliven SF, Michelson S. Compositional stability of artificial heterogeneous tumors in vivo: use of mitomycin C as a cytotoxic probe. Cancer Res 1988; 48:2669-2673.
39. Shi X, Majoros IJ, Patri AK, Bi X, Islam MT, Desai A, et al. Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis. Analyst 2006; 131:374-381.
40. Bielinska AU, Chen C, Johnson J, Baker JR Jr. DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjug Chem 1999; 10:843-850.
41. Antony AC, Kane MA, Portillo RM, Elwood PC, Kolhouse JF. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 1985; 260:14911-14917.
42. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 1996; 93:4897-4902.
43. Jacobs DB, Pipho C. Use of propidium iodide staining and flow cytometry to measure anti-mediated cytotoxicity: resolution of complement-sensitive and resistant target cells. J Immunol Methods 1983; 62:101-108.
44. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31:229-234.
45. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24:148-154.
46. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004; 56:1127-1141.
47. Eliyahu H, Barenholz Y, Domb AJ. Polymers for DNA delivery. Molecules 2005; 10:34-64.
48. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35(Pt 1):61-67.